It is a tamoxifen-inducible mouse model that activates malignant transformation of melanocytes by oncogenic activation of BRAF (BRAFV600E mutation) in the absence of PTEN, a combination that mimics a major process during clinical melanoma progression [8]. This evidence concerns the gene BRAF and melanoma.